|
[1] BLECHACZ B. Cholangiocarcinoma:Current knowledge and new developments[J]. Gut Liver, 2017, 11 (1) :13-26.
|
|
[2] LI JD, XU XF, YU JJ, et al. Updated key points and clinical pathway for NCCN clinical practice guidelines in oncology:Hepatobiliary cancers (Version 1. 2018) [J]. J Clin Hepatol, 2018, 34 (6) :966-977. (in Chinese) 李居东, 徐新飞, 余炯杰, 等.《2018年美国国立综合癌症网络肝胆肿瘤临床实践指南 (V1版) 》更新要点及临床路径[J].临床肝胆病杂志, 2018, 34 (6) :966-977.
|
|
[3] DOUSSOT A, JARNAGIN WR, AZOULAY D, et al. Improving actual survival after hepatectomy for intrahepatic cholangiocarcinoma-still a long way to go[J]. Hepatobiliary Surg Nutr, 2019, 8 (2) :161-163.
|
|
[4] KAPRANOV P, CHENG J, DIKE S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription[J]. Science, 2007, 316 (5830) :1484-1488.
|
|
[5] PONTING CP, OLIVER PL, REIK W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009, 136 (4) :629-641.
|
|
[6] SUN M, KRAUS WL. From discovery to function:The expanding roles of long noncoding RNAs in physiology and disease[J]. Endocr Rev, 2015, 36 (1) :25-64.
|
|
[7] SORENSEN KP, THOMASSEN M, TAN Q, et al. Long noncoding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer[J]. Breast Cancer Res Treat, 2013, 142 (3) :529-536.
|
|
[8] ADELMAN K, EGAN E. Non-coding RNA:More uses for genomic junk[J]. Nature, 2017, 543 (7644) :183-185.
|
|
[9] BHAN A, SOLEIMANI M, MANDAL SS. Long noncoding RNA and cancer:A new paradigm[J]. Cancer Res, 2017, 77 (15) :3965-3981.
|
|
[10] SUN YS, QU Q, PAN JH, et al. Role of lncRNAs in colorectal cancer[J]. Chin J Clin Pharmacol Ther, 2017, 22 (2) :222-227. (in Chinese) 孙跃胜, 屈强, 潘江华, 等.长链非编码RNA在结直肠癌中的作用[J].中国临床药理学与治疗学, 2017, 22 (2) :222-227.
|
|
[11] YANG W, LI Y, SONG X, et al. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing[J].Oncotarget, 2017, 8 (16) :26591-26599.
|
|
[12] YU Y, ZHANG M, LIU J, et al. Long non-coding RNA PVT1promotes cell proliferation and migration by silencing ANGPTL4expression in cholangiocarcinoma[J]. Mol Ther Nucleic Acids, 2018, 13:503-513.
|
|
[13] YAO Y, SUN Y, JIANG Y, et al. Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo[J]. Biomed Pharmacother, 2018, 106:260-266.
|
|
[14] LI Y, CAI Q, LI W, et al. Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth[J]. Biochem Biophys Res Commun, 2018, 504 (4) :654-659.
|
|
[15] VAQUERO J, GUEDJ N, CLAPERON A, et al. Epithelialmesenchymal transition in cholangiocarcinoma:From clinical evidence to regulatory networks[J]. J Hepatology, 2017, 66 (2) :424-441.
|
|
[16] XU Y, WANG Z, JIANG X, et al. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition[J]. Biomed Pharmacother, 2017, 92:17-23.
|
|
[17] ZHANG SH, XIAO JH, CHAI Y, et al. LncRNA-CCAT1 promotes migration, invasion, and EMT in intrahepatic cholangiocarcinoma through suppressing miR-152[J]. Dig Dis Sci, 2017, 62 (11) :3050-3058.
|
|
[18] LU X, ZHOU C, LI R, et al. Long noncoding RNA AFAP1-AS1 promoted tumor growth and invasion in cholangiocarcinoma[J]. Cell Physiol Biochem, 2017, 42 (1) :222-230.
|
|
[19] ZHANG C, LI JY, ZHOU FZ, et al. Long noncoding RNA NEAT1 promotes growth and metastasis of cholangiocarcinoma cells[J]. Oncol Res, 2018, 26 (6) :879-888.
|
|
[20] LI Z, LI J, JI D, et al. Overexpressed long noncoding RNA Sox2ot predicts poor prognosis for cholangiocarcinoma and promotes cell proliferation and invasion[J]. Gene, 2018, 645:131-136.
|
|
[21] QIN X, LU M, ZHOU Y, et al. LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells[J]. Cell Cycle, 2019, 18 (8) :889-897.
|
|
[22] KONG L, WU Q, ZHAO L, et al. Upregulated lncRNA-UCA1contributes to metastasis of bile duct carcinoma through regulation of miR-122/CLIC1 and activation of the ERK/MAPK signaling pathway[J]. Cell Cycle, 2019, 18 (11) :1212-1228.
|
|
[23] TANG L, WANG Y, WANG H, et al. Lnc-RMRP is involved in the progression of cholangiocarcinoma by regulating miR-217[J]. Cancer Sci, 2019, 110 (7) :2166-2179.
|
|
[24] LI J, JIANG X, LI C, et al. LncRNA-MEG3 inhibits cell proliferation and invasion by modulating Bmi1/RNF2 in cholangiocarcinoma[J]. J Cell Physiol, 2019.[Epub ahead of print]
|
|
[25] PARASRAMKA M, YAN IK, WANG X, et al. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma[J]. Molecular Cancer, 2017, 16 (1) :22-34.
|
|
[26] MA SL, LI AJ, HU ZY, et al. Co-expression of the carbamoyl-phosphate synthase 1 gene and its long non-coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma[J]. Mol Med Rep, 2015, 12 (6) :7915-7926.
|
|
[27] QIN W, KANG P, XU Y, et al. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma[J]. Sci Rep, 2018, 8 (1) :12176.
|
|
[28] ANGENARD G, MERDRIGANC A, LOUIS C, et al. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma[J]. Dig Liver Dis, 2019.[Epub ahead of print]
|
|
[29] WANG J, XIE H, LING Q, et al. Coding-noncoding gene expression in intrahepatic cholangiocarcinoma[J]. Transl Res, 2016, 168:107-121.
|
|
[30] SU LH, ZHU XY, ZHANG LY. Diagnosis strategies for intrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2017, 33 (1) :180-183. (in Chinese) 粟立红, 朱新宇, 张缭云.肝内胆管癌的诊断策略[J].临床肝胆病杂志, 2017, 33 (1) :180-183.
|
|
[31] JIANG XM, LI ZL, LI JL, et al. LncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinoma[J]. Eur Rev Med Pharmacol Sci, 2017, 21 (6) :1242-1247.
|
DownLoad: